Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
For more info contact Fas Mosleh (650 468 0401) – FMosleh@Kanzatec.com ©Kanzatec LLC, July 2013
Disclaimer: This report co...
For more info contact Fas Mosleh (650 468 0401) – FMosleh@Kanzatec.com ©Kanzatec LLC, July 2013
Disclaimer: This report co...
Upcoming SlideShare
Loading in …5
×

Geneasys key lab™ system for molecular diagnostics v2

693 views

Published on

Kanzatec LLC, is representing Geneasys exclusively, to divest all the KeyLab patent applications and technology assets. The KeyLab portfolio, which may provide a strategic advantage to one of your clients represents a "Lab on a Chip"—a low cost DNA based diagnostic device (USB), that can be used anywhere, by anybody, using a smart phone, tablet or laptop.

Geneasys has a portfolio of 350+ US patent applications (plus PCT coverage), covering KeyLab, including alternative approaches and ring-fencing the core technology. 17 applications have been allowed already by the USPTO, with the remainder pending



The portfolio has priority dates of 2010 and provides the buyer with a broad set of applications that can be strategically prosecuted to attain excellent future patent protection.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Geneasys key lab™ system for molecular diagnostics v2

  1. 1. For more info contact Fas Mosleh (650 468 0401) – FMosleh@Kanzatec.com ©Kanzatec LLC, July 2013 Disclaimer: This report contains no legal opinion and is purely technical in nature. Therefore, no content of this report should be construed as having any legal weight or being legally dispositive in any manner. The report should not be used for any litigation or dispute related to patent, product or process. Geneasys KeyLab™ System for Molecular Diagnostics Sale of Patent Portfolio and Related IP Assets What is it? • Lab on a chip, low cost DNA based diagnostic device (USB), that can be used anywhere, by anybody using a cellphone or laptop • Can detect up to 48 DNA/RNA markers of infectious or hereditary diseases simultaneously • Process : Plug into USB port, insert swab and process/display results What are we selling? Geneasys has a portfolio of 350+ US patent applications (plus PCT coverage), covering KeyLab, including alternative approaches and ring-fencing the core technology. 17 applications have been allowed already by the USPTO, with the remainder pending :
  2. 2. For more info contact Fas Mosleh (650 468 0401) – FMosleh@Kanzatec.com ©Kanzatec LLC, July 2013 Disclaimer: This report contains no legal opinion and is purely technical in nature. Therefore, no content of this report should be construed as having any legal weight or being legally dispositive in any manner. The report should not be used for any litigation or dispute related to patent, product or process. • Estimated current global market size for Point of Care (human) diagnostics is $14 bn per annum • Molecular Diagnostics (MDx) market currently $5Bn with CAGR of > 15% • Advances in genetics, genomics and molecular science are driving the market • Infectious diseases are the most important applications, followed by cancer and cardiovascular conditions • Drug companion diagnostics development is becoming a major driver Market Opportunity 0 1000 2000 3000 4000 5000 6000 InfectiousDiseases Blood Screening Genotypingand Oncology Pharm acodiagnostics Tissue Typing Sales 2009 Sales 2014 Molecular Diagnostics Market US$M

×